Factors Affecting Pharmacokinetics of Monoclonal Antibodies: A Review Article

Methods and Findings in Experimental and Clinical Pharmacology

Volumn 26, Issue 2, 2004, Pages 123-127

  Iznaga Escobar, Normando ^a   Mishra, A K ^b   Perez Rodriguez R ^a  

^a CENTER OF MOLECULAR IMMUNOLOGY   (Cuba)

^b INSTITUTE OF NUCLEAR MEDICINE AND ALLIED SCIENCES   (India)

Author keywords

Monoclonal antibodies; Pharmacokinetics parameters

Indexed keywords

MONOCLONAL ANTIBODY;

ANTIBODY STRUCTURE; ANTIGENIC MODULATION; CATABOLISM; DOSE RESPONSE; DRUG CLEARANCE; DRUG HALF LIFE; DRUG PENETRATION; DRUG RETENTION; IMMUNOTHERAPY; MOLECULAR WEIGHT; PHARMACOKINETICS; RETICULOENDOTHELIAL SYSTEM; REVIEW;

ANIMALS; ANTIBODIES, MONOCLONAL; FORECASTING; HALF-LIFE; HUMANS; NEOPLASMS;

EID: 1842503153     PISSN: 03790355     EISSN: None     Source Type: Journal    
DOI: 10.1358/mf.2004.26.2.800065     Document Type: Review

References (36)

1. Kohler, G., Milstein, C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 1975, 256: 495-7.
2. Goldstein, N.I., Prewett, M., Zuklys, K., Rockwell, P., Mendelsohn, J. Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model. Clin Cancer Res 1995, 1: 1311-8.
3. Yang, X.D., Jia, X.C.J., Corvalan, J.R.F., Wang, P., Davis, C.G. Development of ABX-EGF, a fully human anti-EGF-R monoclonal antibody, for cancer therapy. Critical Reviews In Oncol And Hemat 2001, 38: 17-23.
4. Crombet. T., Torres, L., Neninger, E. et al. Pharmacological evaluation of humanized anti-epidermal growth factor receptor, monoclonal antibody h-R3, in patients with advanced epithelial-derived cancer. J Immunother 2003, 26: 139-48.
5. 111In-labeled OC-125 antibody in cancer patients compared with the 19-9 antibody. Cancer Res 1987, 47: 6111-7.
6. Hnatowich, D.J., Griffin, T.W., Kosciuczyk, C. et al. Pharmacokinetics of an indium-111-labeled monoclonal antibody in cancer patients. J Nucl Med 1985, 26: 849-58.
7. Zuckier, L.S., Rodriguez, L.D., Scharff, M.D. Immunologic and pharmacologic concepts of monoclonal antibodies. Semin Nucl Med 1989, 19: 166-86.
8. Iznaga-Escobar, N. and Pérez-Rodríguez, R. Monoclonal antibodies for immunoscintigraphy: A revision of the tumor-associated antigen concept. Biotechnology II. Universal Medical Press 1999, 2: 131-8.
9. 99mTc-labeled anti-human epidermal growth factor receptor antibody (ior egf/r3) in patients with tumor of epithelial origin: II. Pharmacokinetics and clearances. J Nucl Med 1998, 39: 1918-27.
10. Mach, J.P., Forni, M., Ritchard, J., Buchegger, F., Carrel, S. et al. Use and limitations of radiolabeled anti-CEA antibodies and their fragments for photo scanning detection of human colorectal carcinomas. Oncodev Biol Med 1980, 1: 49-56.
11. de Bree, R., Roos, J.C., Quak, J.J., den Hollander, W., Snow, G.B., Van Dongen, G.A.M.S. Radioimmunoscintigraphy and biodistribution of technetium-99m-labeled monoclonal antibody U36 in patients with head and neck cancer. Clin Cancer Res 1995, 1: 591-8.
12. 111In-labelted monoclonal antibody in humans. Cancer Res 1987, 47: 3328-36.
13. Kirkwood, J.M., Neumann, R.D., Zoghbi, S.S. et al. Scintigraphic detection of metastatic melanoma using indium 111/DTPA conjugated anti-gp240 antibody (ZME-018). J Clin Oncol 1987, 5: 1247-55.
14. Murray, J.L., Rosenblum, M., Lamki, L. et al. Imaging findings and pharmacokinetics of 111-Indium ZM8-018 monoclonal antibody (MoAB) in malignant melanoma [Abstract]. J Nucl Med 1985, 26: 16.
15. Carrasquillo, J.A., Abrams, P.G., Schroff, R.W. et al. Effect of antibody dose on the imaging and biodistribution of indium-111 9.2.27 anti-melanoma monoclonal antibody. J Nucl Med 1988, 29: 39-47.
16. Carrasquillo, J.A., Bunn, P.A., Keenan, A.M. et al. Radioimmunodetection of Cutaneous T Cell Lymphoma (CTCL) with 111-Indium-labeled T101 monoclonal antibodies. N Engl J Med 1986, 315: 673-80.
17. Carrasquillo, J.A., Colcher, D., Sugarbaker, P. et al. Radioimmunoscintigraphy of colon cancer with Iodine-131 labeled B72.3 monoclonal antibody. J Nucl Med 1988, 29: 1022-30.
18. Baselga, J., Pfister, D., Cooper, M.R. et al. Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin. J Clin Oncol 2000, 18: 904-14.
19. 99mTc-labeled anti-EGF-receptor antibody in patients with tumor of epithelial origin: I. Biodistribution and dosimetry for radioimmunotherapy. J Nucl Med 1998, 39: 15-23.
20. Goldenberg, D.M., Deland, F.H. History and Status of tumor imaging with radiolabeled antibodies. J Biol Response Modif 1983, 1: 121-36.
21. 90Yttrium anti-idiotype radioimmunotherapy of B-cell lymphoma. Proc Am Soc Clin Oncology 1990, 9: 269 [ASCO Abstract].
22. Hong, W.K., Arquette, M., Nabell, L. et al. Efficacy and safety of the anti-epidermal growth factor antibody IMC-C225 in combination with cisplatin in patients with recurrent squamous cell carcinoma of the head and neck refractory to cisplatin containing chemotherapy. Proc Am Soc Clin Oncol 2001, 20: 224a [ASCO Abstract 895].
23. Saltz, L., Rubin, M., Hochster, H. et al. Cetuximab (IMC-225) plus irinotecan (CPT-11) is active in CPT-11 refractory colorectal cancer (CRC) that expresses epidermal growth factor receptor (EGFR). Proc Am Soc Clin Oncol 2001, 20: [ASCO Abstract 7].
24. Ritz, J., Pesando, J.M., Notis-McConarty, J., Sonossman, S.F. Modulation of human acute lymphoblastic leukemia antigen induced by mAb in vitro. J Immunol 1980, 125: 1506-12.
25. Melcher, F. Possible roles of the carbohydrate groups in biological functions of the glycoproteins, immunoglobulins M and G. In: Membrane-Mediated Information. Kent, P.W. (Ed.). Elsevier: New York 1973, 2: 39-56.
26. Morell, A.G., Gregoriadis, G., Scheinberg, I.H. et al. The role of sialic acid in determining the survival of glycoproteins in the circulation. J Biol Chem 1971, 246: 1461-7.
27. Waldmann, T.A., Strober, W. Metabolism of immunoglobulins. Prog Allergy 1969, 13: 1-110.
28. Morell, A., Terry, W.D., Waldmann, T.A. Metabolic properties of IgG subclasses in man. J Clin Invest 1970, 49: 673-80.
29. Morell, A., Riesen, W. Structure, function and catabolism of immunoglobulins. In: Immunotherapy. A Guide to Immunoglobulin Prophylaxis and Therapy. Academic Press: London 1981, 17-26.
30. Etessami, A., Bourhis, J. Cetuximab: Anti-EGF-R monoclonal antibody. Drugs Future 2000, 25(9): 895-9.
31. Mateo, C., Moreno, E., Amour, K., Lombardero, J., Harris, W., Pérez, R. Humanization of a mouse monoclonal antibody that blocks the epidermal growth factor receptor: Recovery of antagonistic activity. Immunotechnology 1997, 3: 71-81.
32. Rodriguez, N., Torres, O., Ramos, M. et al. Efectividad diagnóstica inmunogammagráfica del AcM ior egf/r3 en pacientes con tumores malignos de origen epitelial. Revista Española de Medicina Nuclear 1993, 12 (10) [Abstract].
33. 188Re-direct labeling of monoclonal antibodies for radioimmunotherapy of solid tumors: Biodistribution, normal organ dosimetry and toxicology. Nucl Med and Biol 1998, 25: 441-7.
34. 99mTc para inmunogammagrafía. Revista Española de Medicina Nuclear 1995, 14(1): 10-7.
35. Halpern, S.E., Hagan, P. Effect of protein mass on the pharmacokinetics of murine monoclonal antibodies [letter]. J Nucl Med 1985, 26: 818-9.
36. Yang, X.D., Jia, X.C., Corvalan, J.R., Wang, P., Davis, C.G., Jakobovits, A. Eradication of established tumors by a fully human monoclonal antibody to the epidermal growth factor receptor without concomitant chemotherapy. Cancer Res 1999, 59: 1236-43.